Identification | Back Directory | [Name]
SKL 2001 | [CAS]
909089-13-0 | [Synonyms]
2001 CS-2771 SKL 2001 SKL2001 free base SKL-2001;SKL 2001 SKL2001;SKL-2001;SKL 2001 N-(3-(1H-imidazol-1-yl)propyl)-5-(furan-2-yl)isoxazole-3-carboxamide 5-(furan-2-yl)-N-[3-(1H-imidazol-1-yl)propyl]-1,2-oxazole-3-carboxamide | [Molecular Formula]
C14H14N4O3 | [MDL Number]
MFCD14733081 | [MOL File]
909089-13-0.mol | [Molecular Weight]
286.29 |
Chemical Properties | Back Directory | [Boiling point ]
595.7±50.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 25 mg/ml; DMSO: 25 mg/ml; Ethanol: 25 mg/ml; Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | [form ]
A crystalline solid | [pka]
13.36±0.46(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Description]
SKL2001 is an activator of Wnt/β-catenin signaling.1,2 It increases β-catenin responsive transcription in a cell-based reporter assay in a concentration-dependent manner, increases β-catenin protein levels in HEK293 cells when used at concentrations of 10 and 30 μM, and disrupts the interaction between Axin and β-catenin.1 SKL2001 increases alkaline phosphatase (ALP) activity and mineralization in multipotent mesenchymal ST2 cells in a concentration-dependent manner, indicating increased osteoblastogenesis. SKL2001 (40 μM) reduces HCT116 and HT-29 spheroid growth and inhibits proliferation of HCT116 and HT-29 cells.2 It induces cell cycle arrest at the G0/G1 phase and increases E-cadherin and β-catenin protein levels in HCT116 cells when used at a concentration of 40 μM. | [storage]
Store at -20°C |
|
|